C4 Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for C4 Therapeutics (CCCC).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

11Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$12Upside to Avg. PT+249.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	JP Morgan	Anupam Rama	Initiate	Overweight	$10
Jun 1, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$7→$12
Feb 27, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$5→$7
Feb 23, 2026	Brookline Capital	Leah Rush	PT Raise	Buy	$20→$30
Dec 17, 2025	Barclays	Etzer Darout	PT Cut	Overweight	$10→$5
Dec 2, 2025	TD Cowen	Tyler Van Buren	Initiate	Buy	—
Sep 23, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$5→$10
Sep 23, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$8→$10
Sep 22, 2025	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$6
Sep 17, 2025	Barclays	Etzer Darout	Initiate	Overweight	$8
Sep 15, 2025	Stephens & Co.	Sudan Loganathan	Upgrade	Equal-Weight→Overweight	$3→$6
Sep 4, 2025	Guggenheim	Brad Canino	Initiate	Buy	$8
Dec 19, 2024	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$8→$12
Nov 18, 2024	Stephens & Co.	Sudan Loganathan	Initiate	Equal-Weight	$4
Aug 6, 2024	BMO Capital	Etzer Darout	Maintained	Outperform	$20
May 9, 2024	Wells Fargo	Derek Archila	PT Raise	Equal-Weight	$7→$8
May 9, 2024	Stifel	Bradley Canino	PT Raise	Buy	$13→$14
Feb 26, 2024	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$1→$8
Feb 23, 2024	Stifel	Bradley Canino	PT Raise	Buy	$12→$13
Jan 29, 2024	JP Morgan	Eric Joseph	Upgrade	Underweight→Neutral	$6

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $7.

Benzinga Newsdesk

PRO
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $20 to $30.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.

Benzinga Newsdesk

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

Avi Kapoor

C4 Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

C4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

PRO
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

PRO
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

PRO
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

PRO
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

People Also Watch

People Also Watch

C4 Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

C4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

PROEvercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

PROBarclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

PROBrookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

PROBarclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

PRO
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

PRO
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

PRO
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

PRO
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5